EW-001 JDC milestone approvals
Released
Released
Announcement PDF
1
AdAlta Limited (ASX:1AD) · ABN: 92 120 332 925 · www.adalta.com.au
Suite 1.01, 117 Camberwell Road, Hawthorn East VIC 3123, Australia
ASX Announcement | 5 October 2026
AdAlta Limited (ASX:1AD)
EW-001 Joint Development Committee approves FDA briefing
pack and manufacturing technology transfer plan
AdAlta and its partner Shanghai Cell Therapy Group have formally approved
the next two steps on the path to clinical trials of EW-001 in Australia
Investment highlights
• The latest EW-001 Joint Development Committee meeting with Shanghai Cell Therapy Group
(“SHcell”) was held in Shanghai in late September 2026.
• The committee approved the briefing pack now submitted to the US FDA for AdAlta’s pre-IND
meeting on 4 November 2026 (AEST).
• The committee also approved the plan to transfer SHcell’s EW-001 manufacturing process to
AdAlta’s Australian manufacturing partner.
• Both are formal governance steps that must be passed under the parties’ Development and
Collaboration Agreement.
• Two advanced mesothelioma patients continue in follow-up in the ongoing China clinical study,
including the second complete responder, with next formal assessments expected in early
calendar 2027.
Melbourne, Australia: AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next
generation cellular immunotherapies for solid cancers, today announced that the Joint Development
Committee (“JDC”) for EW-001 (formerly BZDS1901), AdAlta’s lead CAR-T cell therapy for advanced
mesothelioma and other mesothelin-expressing cancers, has approved two important next steps in the
program: the content of the briefing pack for AdAlta’s upcoming pre-IND meeting with the US Food and Drug
Administration (“FDA”), and the plan to transfer EW-001 manufacturing technology from Shanghai Cell
Therapy Group Co Ltd (“SHcell”) to Cell Therapies Pty Ltd (“CTPL”) in Melbourne.
The JDC brings AdAlta and SHcell, the company that originally developed EW-001, together to oversee the
program. Under the parties’ Development and Collaboration Agreement, key steps must be approved by the
JDC before they proceed. The meeting in Shanghai in late September approved both of the steps AdAlta
needs to take next.
AdAlta CEO and Managing Director, Dr Tim Oldham said:
“These are the approvals we needed to take EW-001 to its next stage. SHcell has endorsed both what we
will discuss with the FDA in November and how EW-001 will be made in Melbourne, so we can now move
ahead with both.”
What the JDC approved
• FDA briefing pack. Before a pre-IND meeting, the FDA reviews a detailed document describing
how EW-001 is made and tested, what is known about its safety and effectiveness, and the Phase 1
clinical trial AdAlta proposes to run. Much of that information comes from SHcell, so the JDC’s formal
approval confirms that both partners stand behind the proposals and data being put to the FDA. The
briefing pack has now been submitted on schedule to the FDA. As previously announced, the
meeting is scheduled for 3 November 2026 US time (4 November 2026 AEST).
• Manufacturing technology transfer plan. The plan sets out how SHcell’s rapid, low cost third
generation manufacturing process for EW-001, together with its testing methods and know-how, will
be transferred to CTPL. Making EW-001 in Australia to the standards the FDA expects is an
essential step before Phase 1 clinical trials can begin.
2
Update on patients in China
In July 2026, AdAlta reported that all five patients then remaining on study in SHcell’s investigator-initiated
trials (“IITs”) of EW-001 in China were alive. Further details about these patients are now available. Two of
those patients remain on study (meaning progress is formally and regularly monitored and documented).
How long each patient stays on study is set by the study protocol. As a result:
• the first patient to achieve a complete response, having completed the final study assessment point
two years after treatment with no evidence of cancer returning, has completed the study;
• two patients were assessed as having progressive disease (their cancer had grown relative to
baseline pre-treatment) having previous achieved a partial response and stable disease respectively
and, as per protocol, were withdrawn from formal follow-up; and
• two patients remain on study with planned follow-up: the second complete response patient, who,
as previously reported, has passed one year of survival and is next due for assessment at 18
months, and a patient whose disease remained stable (tumours not growing) at their six month
assessment.
The next formal assessments of both patients remaining on study are expected in the first quarter of
calendar 2027. No patients have yet been treated under the Hainan Boao Lecheng special access approval
announced in September 2026.
Next steps and strategic significance
AdAlta will submit the approved briefing pack to the FDA ahead of the pre-IND meeting. The FDA generally
issues formal written minutes two to four weeks after the meeting, and AdAlta will update the market as
appropriate. In parallel, AdAlta, SHcell and CTPL will proceed with the approved technology transfer plan,
with first Australian manufacturing runs anticipated in the second half of calendar 2026.
For shareholders, the significance is simple: the partnership with SHcell is working as intended. Both
partners have now formally agreed on what will be put to the FDA and on how EW-001 will be made in
Australia – the two foundations of AdAlta’s planned Phase 1 clinical trials and of the value AdAlta aims to
create by bringing EW-001 to Western patients and partners.
To view a summary, and engage in discussion about this announcement visit AdAlta’s InvestorHub here:
https://investorhub.adalta.com.au/link/PR1g3r
This ASX announcement has been authorised for release by the Board of AdAlta Limited (ASX:1AD).
For further information, please contact:
AdAlta Limited (ASX:1AD)
Tim Oldham
CEO & Managing Director
P: +61 403 446 665
E: ir@adalta.com.au
About EW-001 (formerly BZDS1901)
EW-001 is a novel, first in class, CAR-T cell therapy designed to treat mesothelioma (a rare but rapidly fatal
cancer usually linked to asbestos exposure) and with possible application in more than ten other cancers.
CAR-T cell therapies are living drugs manufactured from a patient’s own immune cells that are engineered to
be able to find and kill cancer. They offer the potential to provide durable cancer control or cure from a single
treatment. EW-001 targets a protein called mesothelin that is highly expressed in many cancers. EW-001 is
also engineered to produce a protein called a checkpoint inhibitor that is designed to protect the CAR-T cell
from a key defensive mechanism used by cancers.
Patients diagnosed with mesothelioma today are typically treated with surgery if possible and then initial or
first line drug treatments are chemotherapy or immunotherapy. Once a patient has relapsed after initial
3
therapy, second line treatment options are even more limited and outcomes are much poorer. Current
treatments typically deliver: 1,2
• Tumour shrinkage (Overall Response) in only 40-44% of first line patients and 11-29% of second
and subsequent line patients
• Complete tumour clearance (Complete Response) is rare and seen in less than 3% of first line
patients and almost never in second line patients
• Median survival (at which point 50% of patients will have died) is often only 14-18 months for first
line and 8-10 months for second line treatment, with tumours beginning to grow again typically after
only half that time.
By contrast, EW-001 clinical studies in relapsed or advanced mesothelioma patients (second line and later)
in China have reported:
• Up to 50% Overall Response rate (tumour shrinkage)
• Up to 20% Complete Response rate (complete tumour clearance)
• Two patients achieving Complete Responses have now reached two and one year survival
milestones respectively with no evidence of cancer returning providing evidence of durability of
response
• Median overall survival has not yet been reached in the current generation manufacturing process,
however an earlier generation of EW-001 achieved more than 25 months median survival
These early results suggest EW-001 may offer an exciting potential new treatment option for patients with
few alternatives. EW-001 has not yet received regulatory approval for general commercial launch anywhere
in the world.
About AdAlta
AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular
immunotherapies for the treatment of solid cancers.
Through its ‘East to West’ strategy, the Company is integrating Asia's prowess in T cell therapy development
with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway
connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients.
AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing
and conduct Phase I clinical studies with potential to position each product for on-licensing to larger
biopharmaceutical companies for potential registrational studies and commercialization.
AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy
products supported by clinical data in solid cancers. The company adopts a capital efficient business model
delivering a rapid return on investment in each project that is replicable and provides opportunities to scale
across multiple products.
Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies.
AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow
at a compound annual growth rate of 34% to reach US$20.3 billion by 2028.
AdAlta’s other assets include first in class fusion protein, AD-214, that takes a whole new approach to fibrotic
diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis and
WD-34, a novel pan-strain inhibitor of malaria, Babesia and Toxoplasma parasites. Following demonstration
of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is
available for partnering. WD-34 is seeking grant funding to optimize the molecule format to enable single
dose seasonal prophylaxis.
To learn more, please visit: www.adalta.com.au
1
CHECKMATE-743 study (nivolumab + ipilimumab against chemotherapy): S Peters et al, Annals of Oncology, 2022 (33) 488;
https://doi.org/10.1016/j.annonc.2022.01.074
2
See for example CONFIRM study (nivolumab against placebo): DA Fennell et al, Lancet Oncol 2021 (22) 1530
4
For more information
Join our InvestorHub
Follow us on LinkedIn
Follow us on X (formerly Twitter)
Share your feedback
Discover